Influence of intraperitoneal instillation of local anaesthetics in bariatric surgery on pain optimisation, reduction of drug consumption, minimisation of side effects and reduction of hospital length of stay

Influence of intraperitoneal instillation of local anaesthetics in bariatric surgery on pain optimisation, reduction of drug consumption, minimisation of side effects and reduction of hospital length of stay - IPILA-BS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00036334

Enrollment

100

Registered

2025-03-05

Start date

2025-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E66

Interventions

Group 1: Intraperitoneal instillation of Ropivacaine (0.2%, 100 ml) at the beginning of the operation. Group 2: Intraperitoneal instillation of NaCl solution (0.9%, 100 ml) at the beginning of the ope

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Body Mass Index (BMI) > 40 or BMI > 35 with at least one comorbidity (e.g., diabetes mellitus, osteoarthritis, hypertension, and/or obstructive sleep apnea). Approval for surgery after a multidisciplinary bariatric evaluation

Exclusion criteria

Exclusion criteria: Psychological unfitness after screening. American Society of Anesthesiologists (ASA) class 4 or higher. Previous bariatric or stomach surgery. Age 65 years. Allergy to Ropivacaine.

Design outcomes

Primary

Measure	Time frame
Combined scores of abdominal, trocar site, and shoulder pain after bariatric surgery at multiple time points	—

Secondary

Measure	Time frame
Comparison of opioid consumption. Evaluation of side effects such as nausea and vomiting. Analysis of hospital length of stay.	—

Countries

Germany

Contacts

Public ContactMark Philipp

Klinik für Allgemeine Chirurgie, Thorax, Gefäß- und Transplantationschirurgie Universitätsmedizin Rostock

mark.philipp@med.uni-rostock.de+49381494146174

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026